Roche has discontinued its involvement with PDL BioPharma in the development of daclizumab in asthma, which the companies had been co-developing since 2004. The decision, following a portfolio review at Roche, has no effect on the companies’ ongoing collaboration to co-develop daclizumab in transplant maintenance, and the companies intend to proceed with planned Phase II studies for the transplant indication during 2007. As a result, PDL now holds exclusive development and commercial ...